Professor Gabi Dachs completed her undergraduate and PhD studies in Cape Town, South Africa, followed by postdoctoral work at the MRC Harwell in the United Kingdom.
Prior to joining the University of Otago in Christchurch, Professor Dachs worked as senior scientist at the Gray Cancer Institute in London, UK.
Professor Gabi Dachs is interested in why human tumours are difficult to treat, and in new ways of treating them.
Current research interests at present include:
- Can we dampen the activity of the global transcription factor HIF-1 using vitamin C? Can we reduce tumour growth in mice using vitamin C? Can we increase vitamin C in cancer cells using gene therapy? What is the relationship between ascorbate and HIF-1 in tumours from kidney cancer patients?
- Why do obese cancer patients often fare worse than non-obese patients? Can we identify the molecular factors associated with obesity in cancer? What effect do these obesity-related factors have on chemotherapy?
- Which human enzymes are responsible for the activation of novel anticancer prodrugs (in collaboration with Auckland Cancer Society Research Centre)? Can this knowledge guide clinical use of these agents?
- Can we improve gene directed enzyme prodrug therapy combinations to target solid tumours or their vasculature?
In the media
Professor Gabi Dachs was featured in Radio New Zealand's The Science Of... Vitamin C in August 2017.
Praditi, C., Bozonet, S. M., Dachs, G. U., & Vissers, M. C. M. (2023). Ascorbate uptake and retention by breast cancer cell lines and the intracellular distribution of sodium-dependent vitamin C transporter 2. Antioxidants, 12, 1929. doi: 10.3390/antiox12111929
de Vries, M., Stewart, T., Ireton, T., Keelan, K., Jordan, J., Robinson, B. A., & Dachs, G. U. (2023). Patients’ and carers’ priorities for cancer research in Aotearoa/New Zealand. PLoS ONE, 18(8), e0290321. doi: 10.1371/journal.pone.0290321
Dachs, G. (2023, May). Scatterlings: Cancer research across continents and time. University of Otago, Christchurch, New Zealand. [Inaugural Professorial Lecture].
Crake, R. L. I., Burgess, E. R., Wiggins, G. A. R., Magon, N. J., Das, A. B., Vissers, M. C. M., Morrin, H. R., Royds, J. A., Slatter, T. L., Robinson, B. A., Phillips, E., & Dachs, G. U. (2022). Ascorbate content of clinical glioma tissues is related to tumour grade and to global levels of 5-hydroxymethyl cytosine. Scientific Reports, 12, 14845. doi: 10.1038/s41598-022-19032-8
Burgess, E. R., Crake, R. L. I., Phillips, E., Morrin, H. R., Royds, J. A., Slatter, T. L., Wiggins, G. A. R., Vissers, M. C. M., Robinson, B. A., & Dachs, G. U. (2022). Increased ascorbate content of glioblastoma is associated with a suppressed hypoxic response and improved patient survival. Frontiers in Oncology, 12, 829524. doi: 10.3389/fonc.2022.829524